Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

  • End date
    Dec 31, 2021
  • participants needed
  • sponsor
    The HIV Netherlands Australia Thailand Research Collaboration
Updated on 26 January 2021
integrase inhibitors
HIV Vaccine
hiv-1 infection


This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults


The fundamental principle of regimen switching is to maintain viral suppression without jeopardizing future treatment options. The reasons to consider regimen switching in the viral suppressed population are to simplify the regimen by reducing the pill burden and dosing frequency, to increase the tolerability, reduce the adverse effects as well as long-term toxicities, to prevent drug-to-drug interactions and to avoid the dietary requirements.

Generic TAF/E/D (tenofovir alafenamide 25mg/emtricitabine 200mg/dolutegravir 50 mg), a single-tablet once daily regimen, will be an affordable regimen with the potential characteristics such as reduced pill burden, less drug to drug interaction and toxicities. The generic form (Mylan) is recently received the tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Whether DTG-containing regimen is a better option than protease inhibitors among resource-limited settings during the decisions for second-line treatment options, is needed to be evaluated.

All participants will be switched from their pre-study ART regimen to a single tablet regimen (STR) of TAF/FTC/DTG 25/200/50mg once daily.

Condition HIV, HIV positive, HIV infection, AIDS Vaccines, HIV (Pediatric), HIV Infections, human immunodeficiency virus, hiv disease, HIV Vaccine, hiv vaccines
Treatment generic single tablet TAF/FTC/DTG
Clinical Study IdentifierNCT03727152
SponsorThe HIV Netherlands Australia Thailand Research Collaboration
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Documented HIV-1 infection
Aged 18 years old
Female participant may be eligible to participate if she
is of non-childbearing potential defined as either post-menopausal (12 months
of spontaneous amenorrhea or >=54 years of age) or physically incapable of
becoming pregnant with documented tubal ligation, hysterectomy, or bilateral
oophorectomy or, is of child-bearing potential, with a negative pregnancy test
at both Screening and week 0 and agrees to use one of the protocol-defined
methods of contraception to avoid pregnancy
\. On current ART for at least 6 months prior to study entry
\. Current ART includes boosted protease inhibitors
\. No more than one HIV-1 plasma RNA >50 copies/mL and <200 copies/L (only
one 'blip') in the past 6 months with a subsequent HIV-1 plasma RNA <50
\. HIV-1 plasma RNA <50 copies/mL at screening visit
\. No prior or current exposure to integrase strand transfer inhibitor
\. Have signed the informed consent form

Exclusion Criteria

Breastfeeding female
Pregnancy or positive UPT at screening
Calculated creatinine clearance as estimated by Cockcroft-Gault equation (CrCl) <60 mL/min
Alanine aminotransferase (ALT) >2.5 x ULN
Concomitant use of any of the following medications
(1) aluminum and magnesium-containing antacids, proton-pump inhibitors (2)
anticonvulsants: carbamazepine, oxcarbamazepine, phenobarbital, phenytoin (3)
antimycobacterials: rifabutin, rifampin, rifapentine (4) St. John's wort
\. Alcohol or drug abuse that, in the opinion of the investigator, would
interfere with completion of study procedures
\. Any serious illness that, in the opinion of the investigator, would
interfere with completion of study procedures
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note